Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Therapeutics PLC

www.summitplc.com

Latest From Summit Therapeutics PLC

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical

Pipeline Watch: Topline Phase III Results For Tenapanor, Abemaciclib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Readouts For Gilenya, Duvelisib, Trimbow

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity

Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.

Infectious Diseases Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • VASTox PLC
  • Summit PLC
  • Summit Corp. PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Summit Therapeutics PLC
  • Senior Management
  • Glyn Edwards, CEO
    Erik Ostrowski, CFO
    David Roblin, PhD, COO & CMO
  • Contact Info
  • Summit Therapeutics PLC
    Phone: (44) (0)1235 443 939
    136a Eastern Ave.
    Milton Park
    Abingdon, OX14 4SB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register